Image Source: Unsplash

Deals and Financings

• Japan’s Takeda acquired global rights to an Alzheimer’s therapy developed by AC Immune SA of Switzerland for $100 million upfront and up to $2.1 billion in milestones;
• San Diego’s Erasca in-licensed two China-developed pre-clinical RAS candidates in two separate agreements with a total value of $359 million;
• Shenzhen Beimei Pharma acquired greater China rights for Twyneo®, a therapy for acne vulgaris, from Israel’s Sol-Gel (SLGL) for $15 million;

Trials and Approvals

• Shanghai’s Zai Lab reported China’s NMPA approved repotrectinib for adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer;
• Shanghai Everest Medicines launched Nefecon®, a treatment for IgA nephropathy in China, a glomerular disease that can cause end-stage renal disease;
• Suzhou Ractigen Therapeutics announced approval of its China IND for RAG-17 as a therapy for Amyotrophic Lateral Sclerosis;
• Beijing InnoCare Pharma completed enrollment in a China Phase II trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor for psoriasis therapy;
• Shanghai Mabwell reported positive data from a China trial of its novel Nectin-4-targeting ADC for triple-negative breast cancer;
• Nanjing IASO Bio announced a single-cell analysis was published in a scientific journal for its anti-BCMA CAR T cell therapy that targets neuromyelitis optica spectrum disorder.

More By This Author:

Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal